Table 4.
Biochemical recurrence free, clinical recurrence free and overall survival time for UBE2O expression—173 from 335 patients with prostate cancer could be evaluated for survival.
| UBE2O Grade | Total | Event | Censored | Survival Time | Survival Time | ||||
|---|---|---|---|---|---|---|---|---|---|
| Mean ± SE | 95% CI | Median ± SE | 95% CI | ||||||
| Lower | Upper | Lower | Upper | ||||||
| Biochemical recurrence free survival | |||||||||
| 1 | 31 | 5 | 26 | 7.77 ± 0.66 | 6.47 | 9.06 | |||
| 2 | 72 | 10 | 62 | 11.39 ± 0.68 | 10.07 | 12.72 | |||
| 3 | 70 | 14 | 56 | 9.43 ± 0.57 | 8.32 | 10.55 | |||
| Total | 173 | 29 | 144 | 10.77 ± 0.54 | 9.71 | 11.83 | |||
| Clinical recurrence free survival | |||||||||
| 1 | 31 | 1 | 30 | 10.23 ± 0.51 | 9.23 | 11.23 | |||
| 2 | 72 | 5 | 67 | 11.82 ± 0.45 | 10.94 | 12.70 | 12.42 ± 3.87 | 4.84 | 20.00 |
| 3 | 70 | 5 | 65 | 11.31 ± 0.44 | 10.45 | 12.18 | |||
| Total | 173 | 11 | 162 | 11.74 ± 0.34 | 11.08 | 12.40 | 12.42 ± 2.40 | 7.72 | 17.11 |
| Overall survival | |||||||||
| 1 | 31 | 7 | 24 | 8.47 ± 0.70 | 7.10 | 9.84 | |||
| 2 | 72 | 17 | 55 | 9.65 ± 0.60 | 8.47 | 10.84 | 10.97 ± 1.72 | 7.61 | 14.33 |
| 3 | 70 | 11 | 59 | 10.63 ± 0.46 | 9.74 | 11.53 | 12.11 ± 3.07 | 6.09 | 18.13 |
| Total | 173 | 35 | 138 | 10.17 ± 0.39 | 9.41 | 10.94 | 12.11 ± 1.11 | 9.93 | 14.29 |
UBE2O grade—0: negative, 1: weak, 2: moderate, 3: strong.